NCT00909389View on ClinicalTrials.gov

Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)

CompletedOBSERVATIONAL

Enrollment

4,748

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Hypercholesterolemia

Interventions

DRUG

Vytorin (R) (Ezetimibe + Simvastatin)

Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00909389 - Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647) | Biotech Hunter | Biotech Hunter